MyHeritage bietet globale DNA Tests, für die Aufdeckung ethnischer Herkunft und der Herstellung neuer ... - Satellite PR News (press release)

Submit the press release

Robo Advisor launches year long education initiative to save Canadians $1,000,000,000 in investment fees over their lifetimes.

TORONTO, ONTARIO, CANADA, February 15, 2017 /EINPresswire.com/ — Nest Wealth, Canada’s largest independent digital wealth manager, announced today its launch of the Billion Dollar Challenge. The leading digital wealth management platform is starting a year long series of educational initiatives in an effort to help Canadians save $1,000,000,000 in investment fees over their lifetimes through improved financial literacy, better investing solutions, and increased awareness around fees.

“We believe the more Canadians know about the impact of fees on their savings, the greater their ability to invest wisely and create wealth,” said Randy Cass, founder and CEO of Nest Wealth. “Nest Wealth has already positioned our clients to save more than $31,000,000 in investment fees, but we want to do more. We are launching the Billion Dollar Challenge to give Canadians the tools they need to truly understand how to avoid high fees and achieve their financial goals.”

Last year Nest Wealth undertook a study that showed after buying a house investment fees can be the average Canadian’s single largest expense, costing the typical investor a staggering $323,654.40 over their lifetime. According to a recent Morningstar survey Canadians continue to pay some of the highest mutual fund fees in the developed world.

2017 will be the first full year of increased disclosure of investment fees under new regulatory guidelines in Canada. “For the first time investors will clearly see how much they are paying in fees and be in a position to decide if they are getting value for those fees,” says Cass.

Over the next year, as part of the Billion Dollar Challenge, Nest Wealth will be rolling out print, digital, and in-person initiatives to increase consumer awareness around how high fees can destroy savings. Starting today, Canadians can go to www.nestwealth.com/billion-dollar-challenge to obtain personalized information about how much they’re likely to pay in investment fees over the next twenty years if they remain in their current funds and don’t take action.

“Everyone says that Canadians have a ‘saving problem’ but the truth is we have a ‘fee problem’,” explains Cass. “With the right information and tools, Canadians can make smarter decisions about how and where to invest. The Billion Dollar Challenge is designed to give Canadians these tools.”

To learn more about the Billion Dollar Challenge visit www.nestwealth.com/billion-dollar-challenge. Join the conversation on social media using the hashtag #SavingABillion.

About Nest Wealth

Nest Wealth is a Canadian digital wealth management provider that offers both direct-to-investor solutions through www.nestwealth.com and advanced business solutions through its Nest Wealth Pro product. The only online advisor in Canada to charge clients a flat fee, Nest Wealth makes it easy for investors to obtain sophisticated wealth management tailored to their long-term goals. Nest Wealth’s Pro product provides wealth management firms with a seamless and affordable online portfolio management solution for their clients through simple onboarding, greater transparency, and fully integrated back office and compliance functionality.

For further information, please contact:

Kate Smalley,
Nest Wealth
416-902-6014
email us here

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             [email protected]
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Consumer Electronics, Telematics and Vehicle Electronics, Electric and Hybrid Vehicles
                    

CONTACT:
                    Deb Montner, Montner Tech PR
                    (203) 226-9290
                    [email protected]

Submit the press release

Submit the press release

/EIN News/ — Dublin, Feb. 16, 2017 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of the “Wireless Charging 2017-2027: Phones, Cars etc.” report to their offering.

This unique commercially oriented report has 180+ pages packed with detailed market and technical analysis with many new infograms, conference slides, roadmaps and ten year forecasts 2017-2027. The Executive Summary and Conclusions is insightful, detailed yet easily assimilated.

An introduction gives an overview of the background and technologies with a frank assessment of why most manufacturers and analysts have been over-optimistic about the use, though not always the deployment of these systems in the past and the significance for the future of new capabilities such as long range phone charging. Other chapters embrace the different applications, technologies and roadmaps.

The report primarily discusses mobile phone and electric cars charging but showing how much the same arguments apply to many electrical and electronic goods, particularly mobile ones. Most analysts forecasting sales of contactless charging systems for phones and pure electric cars have over-estimated both over the last 15 years. In response to customer demands, may other aspects were being fixed first. People wanted better features and more of them with their phones, larger screens and so on.

The report is extremely comprehensive. It looks at the activities of many developers and manufacturers and their potential customers and users. The enthusiasm of suppliers shown in new interviews is tempered by twenty years of experience for the analyst and new opinion from key companies such as Ford assessing the technology in 2017. Having recently researched reports on Fuel cell vehicles, energy independent electric vehicles, better batteries, better energy harvesting phones and robot chargers render wireless charging unnecessary.

The report reveals how mobile phone users do not want contactless charging as such but rather they need ubiquitous charging without carrying a charger around or better still, no loss of use through lack of charge. It contrasts electric vehicles where the act of plugging in public places can he a physical strain, dirty and dangerous but the environment is more challenging with roads being dug up, animals getting irradiated and ground clearance varying greatly and obscuration a problem.

Key Topics Covered:

1. Executive Summary And Conclusions

2. Introduction

3. Wireless Charging Of Portable Electronic Devices

4. Wireless Charging For Vehicles When Stationary

5. Dynamic Charging Of Vehicles

6. Alternatives To Wireless Charging For Vehicles

7. Examples Of Interviews

Companies Mentioned

• ABB
• AirFuel
• Ampyx Power
• Apple
• BMW
• Chevrolet
• EnerKite
• Energous
• Evatran
• Fraunhofer
• Google Makani
• Hevo Power
• Hyundai-Kia
• Idaho State Laboratory
• Infineon
• Kitegen
• Kitemill
• Korea Advanced Institute of Science and Technology
• Mojo USA
• Nanyang
• Nissan
• Oak Ridge National Laboratory
• Ossia Cota
• Qualcomm
• TDK Japan
• Tenneco Automotive Operating Company
• Tesla
• TwingTec
• Volkswagen
• Volvo
• Wi-Charge
• XALT Energy
• Yutong
• ZTE China
• e-Wind

For more information about this report visit http://www.researchandmarkets.com/research/8pg94l/wireless_charging

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             [email protected]
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Consumer Electronics, Telematics and Vehicle Electronics, Electric and Hybrid Vehicles
                    

Submit the press release

BEVERLY, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) — Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today provides a general business update, corporate outlook for upcoming clinical milestones for its first-in-class drug candidates and select financial results for the second quarter of the fiscal year 2017 ended December 31, 2016.  A comprehensive review of the latest quarter reported is available through Cellceutix’s recently submitted Form 10-Q with the Securities and Exchange Commission at www.sec.gov and on the Cellceutix website.

/EIN News/ — Portfolio Development

The second quarter of fiscal 2017 and the start of our third quarter proved very positive for Cellceutix’s three lead compounds, Brilacidin, Prurisol and Kevetrin.  The past few months laid the groundwork for some fast-approaching milestones that represent pivotal moments for Cellceutix.  As mentioned by management in previous news releases, a primary focus for the 2017 calendar year is completing work necessary to forge partnerships with larger pharmaceutical companies presently engaged with Cellceutix, some under Confidential Disclosure Agreements (CDAs).  Should outcomes from ongoing clinical studies yield favorable results, the Company is optimistic that it will be able to capitalize on the data with respect to a partnership.  Securing partnerships would generate substantial shareholder value, while also helping to advance the Company’s innovative drug candidates toward market approval, benefiting patients in need of additional safe and effective treatment options.

• Brilacidin—Oral Mucositis (Phase 2 Trial)

  – Enrolling 60 patients, the study is evaluating Brilacidin as an oral rinse, 3 times daily for 7 weeks, to prevent and control Oral Mucositis (OM) in patients receiving chemoradiation therapy for head and neck cancer. Even though over 400,000 patients in the U.S. suffer from this condition, presently there are no approved drugs for the treatment of OM in this population, with only limited palliative care options available. Cellceutix’s goal with this trial is to show that Brilacidin has dual functionality in not only shortening the duration and intensity of OM in patients with head and neck cancers, but also preventing the onset of the condition, an accomplishment no other pharmaceutical company has achieved.
  -Upcoming Milestone:  Interim analysis of the Phase 2 trial is expected in approximately 6 to 8 weeks.

• Brilacidin—Inflammatory Bowel Diseases Ulcerative Proctitis/Proctosigmoiditis (Phase 2a Trial)– This Proof-of-Concept trial includes enrolling 18 patients divided evenly into three cohorts. Review of safety data from the first 6 patients revealed that Brilacidin, administered for 6 weeks as a retention enema, at 50 mg once daily, appeared well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were also demonstrated, as measured by physician assessments and patient reported outcomes, further supported with endoscopic evaluation. Brilacidin may show greater efficacy at higher dosing levels in the trial, which are comprised of 100 mg for the current cohort and 200 mg for the third cohort.  Cellceutix believes that a successful trial creates an opportunity to explore Brilacidin for an array of other hard-to-treat Inflammatory Bowel Diseases that current lack effective therapeutics.
  – Upcoming Milestone:  Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks.  The trial is anticipated to be completed in 2Q2017.

Over the next month to two months, Cellceutix expects to have interim data from both Brilacidin trials.  This is particularly important for the development of Brilacidin and pursuit of partnerships as the data can provide clinical evidence of the immunomodulatory and anti-inflammatory properties of Brilacidin for indications that represent areas of unmet medical needs.

• Prurisol – Chronic Plaque Psoriasis (Phase 2b Trial)– Subject recruitment is now ongoing across the United States.  The study increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which was shown to be well-tolerated in a successfully completed Phase 2a trial, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling approximately 189 patients with moderate to severe chronic plaque psoriasis, treatment duration is 12 weeks (84 days). Primary efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). The Company believes now is an opportune time to develop an oral treatment for psoriasis given that currently available treatment options are limited, with many not easily administered and often associated with undesirable side effects.

• Kevetrin – Advanced Ovarian Cancer (Phase 2a Trial)– As disclosed on February 10, 2017, a Phase 2a trial of Kevetrin (CTIX-KEV-201) has commenced.  This is an open-label study evaluating the safety, tolerability, and pharmacokinetics of Kevetrin, as well as changes in select biomarkers and objective tumor response when administered to patients with platinum-resistant/refractory ovarian cancer. The clinical trial comprises two different short-term treatment regimens and will enroll an estimated 10 patients. The trial will directly inform how Kevetrin modulates the p53 signaling pathway.  Cellceutix is consulting with a world renowned expert on p53 and a member of the National Academy of Sciences who helped design the study, which is intended to provide potential partners key information on the mechanism of action of the novel compound.

“I think it is pretty easy to see why we are thrilled at our prospects with four different mid-stage trials ongoing,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix.  “Each study has a valuable component in demonstrating the robustness and potential of our pipeline and I greatly look forward to what I suspect will be a 2017 with a steady flow of information across all four trials.”

“Success in any one of our mid-phase trials could instantly transform the Company overnight,” commented Cellceutix Chief Executive Officer Leo Ehrlich. “Having already engaged in productive discussions with large pharmaceutical companies, Cellceutix remains partnership-focused in 2017. Potentially life-saving drugs and tremendous value creation await patients and shareholders alike as we strive to deliver compelling trial results.”

Select Financial Results for the Second Quarter of Fiscal 2017

The current primary potential source of cash available to the Company are equity investments through its $30.0 million equity purchase agreement with Aspire Capital signed in March 2015. The Company has financed its operations to date through the sale of its common stock. The Company had raised approximately $11.0 million from initiation of the equity purchase agreement with Aspire Capital through the three months ended December 31, 2016, leaving approximately $19.0 million available.  Additionally, as of December 31, 2016, Cellceutix had approximately $3.9 million in cash on hand.

For the three months ended December 31, 2016, the Company’s net loss was approximately $3.36 million, or $0.03 per share, compared to a net loss of $3.32 million, or $0.03 per share, for the three months ended December 31, 2015.

Alerts:
Sign-up for Cellceutix email alerts is available at: www.cellceutix.com/email-alerts

About Cellceutix
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix’s psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first cohort of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause Cellceutix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT
                    Cellceutix Corporation
                    Leo Ehrlich
                    [email protected]

FOR FURTHER INFORMATION CONTACT:
                    Stephen Swett
                    T: (203) 614-0141
                    E: [email protected]

INVESTOR AND MEDIA CONTACT
                    Cellceutix Corporation
                    Leo Ehrlich
                    [email protected]

Submit the press release

/EINPresswire.com/ — NETCONG, NJ–(Marketwired – Feb 16, 2017) – Breaking Games, an award-winning game publisher and manufacturer, announced that they will be highlighting over a dozen new tabletop games, along with its designers, in their booth — Booth 6911, First Level (six booths in a row along the right wall) — at this year’s Toy Fair. Earlier this week, Breaking Games also announced they will be entering the consumer electronics industry with Boogie Dice, the world’s first-ever self-rolling dice, and the toy space with Pixel Pals, collectible pixel-art inspired figures.

“We launched at Toy Fair exactly two years ago, and Breaking Games has been going at breakneck speeds ever since,” said Shari Spiro, Breaking Games’ CEO. “Through it all, we’ve always worked collaboratively with our independent game designers to help realize their aspirations by publishing and promoting their titles. We have some surprising and fantastic new tabletop games that we’re showcasing at this year’s Toy Fair — truly something for everyone.” 

NEW 2017 BREAKING GAME TITLES

Q2 2017
Aura

• Designer: Michael Orion
• Stats: Ages 8+, 2-4 players
• MSRP: $25
• Aura blends modern mechanics with classic simplicity. Players duel with their own deck of cards, where each suit is shown on the card backs, giving the effect of a visible aura.

The Kings Abbey – Second Edition

• Designer: Randy Rathert
• Stats: Ages 14+, 1-5 players
• MSRP: $60
• Players build towers and town buildings, complete crusades, gather resources, and protect against the Dark Ages in this fun and deep strategy game.

Q2 2017 – cont’d.
Asking For Trobils

• Designer: Chris Strain
• Stats: Ages 10+, 2-7 players
• MSRP: $45
• Asking for Trobils is a fun, wacky family game, where players are Trobil Hunters in spaceships stopping space pests from destroying planet Paradise.

Q3 2017
Sparkle*Kitty

• Designer: Manny Vega
• Stats: Ages 6+, 4-8 players
• MSRP: $20 (exact price TBD)
• Nobody puts princess in a tower! Sparkle*Kitty is an adorably fun, social, and magical spell card game for all ages, sizes and genders.

Trellis

• Designer: Teale Fristoe
• Stats: Ages 8+, 2-4 players
• MSRP:$25 (exact price TBD)
• Trellis is a game of Zen and blossoms. Each tile adds more vines and an opportunity to play flowers. First to play all their flowers completes the Trellis.

Flippin Monsters

• Designer: Chris Strain
• Stats: Ages 8+, 2-4 players
• MSRP: $15 (exact price TBD)
• A strategic and fun memory and set collection game about catching monsters who like candy and socks.

Expancity

• Designer: Alex Cutler-Freese
• Stats: Ages 10+, 2-4 players
• MSRP: $50 (exact price TBD)
• The Skyline’s the limit! Expancity has players build a 3D city together, competing to fulfill contracts and have the most valuable buildings.

Dungeons are Dangerous!

• Designer: Paul Peterson
• Stats: 13+, 3-5 players
• MSRP: $25 (exact price TBD)
• Players will use their best excuses to avoid another adventure in a treacherous dungeon because … dungeons ARE DANGEROUS!

Q3 2017 – cont’d
Letter Tycoon: Captains of Industry

• Designer: Brad Brooks
• Stats: 8+, 2-5 players, requires original Letter Tycoon game
• MSRP: $10 (exact price TBD)
• In Letter Tycoon: Captains of Industry, players mix and match new rules to the original award-winning, Mensa-selected game, Letter Tycoon, including global tycoon powers, grand skyscrapers and challenging regulations.

Stripes

• Designer: Maxine Ekl
• Stats: Ages 8+, 3-5 players
• MSRP: $20 (exact price TBD)
• Players race to be the first to make a single horizontal stripe across seven cards by flipping, shifting, trading, and more.

Q4 2017
Rise of Tribes

• Designer: Brad Brooks
• Stats: Ages 10+, 2-4 players
• MSRP: $40 (exact price TBD)
• Players lead their prehistoric tribes to explore new lands, gather resources and discover new tools in an attempt to rise to greatness. Choose to build villages, raid neighbors or maybe even hunt a mammoth.

Treasure Tide

• Designer: James O’ Connor
• Stats: Ages 6+, 2-4 players
• MSRP: TBD
• Treasure Tide is an arcade-style plunder-pushing game that has players racing to collect the most loot from a wrecked pirate ship. Gather gold, gems and perhaps pieces of the fabled buried treasure map!

Infamous: The Pirate Wars

• Designer: Dan Blanchett
• Stats: Ages 10+, 2-4 players
• MSRP: TBD
• Infamous: The Pirate Wars is a strategic card game where you take on the role of history’s most notorious rogues. Capture ships, seize cargo, embark on lucrative campaigns, and prey on the vessels of fellow pirates, all in the pursuit of infamy.

BOOGIE DICE AND PIXEL PALS
Launching in fall 2017 launch with an MSRP of $49.99, Boogie Dice is the world’s first sound-activated, self-rolling dice. Users simply clap their hands, snap their fingers or bang on the table, and the dice starts to “boogie” by itself. The Boogie Dice app lets users program the dice to change color, roll longer, faster or higher, as well as stop the dice on command.

Breaking Games made its foray this past summer into the toy world with the launch of Pixel Pals, where pixels become plastic and 2D characters turn into 3D entertainment. Available for an MSRP of $25 each, Pixel Pals are collectible pixel art-inspired figures that come in arcade cabinet-styled boxes

“To me, there is nothing better than playing tabletop games — you laugh, you bond, you compete, you spend quality time with one another,” concluded Spiro. “While we’ve made some amazing accomplishments in just a short amount of time, at the heart of all we do, it’s about connecting people in a way that’s engaging and meaningful, whether through board games, card games, toys, or dice that actually boogie.” 

For more information, please visit:

About Breaking Games
Founded by Shari Spiro of Ad Magic — manufacturer of Cards Against Humanity, Exploding Kittens, and many more — Breaking Games is a publishing company dedicated to getting the latest indie games to players’ tabletops. In its first two years, Breaking Games developed Mensa Select winners for 2015 and 2016, as well as IndieCade and Tabletop Deathmatch Finalists. They have multiple games in Target stores nationwide, and Miss Spiro was awarded EY’s Entrepreneur of the Year 2016 in New Jersey. Breaking Games uber-promotes their game designers because they are the rock stars of tabletop gaming. The designers work directly with the Breaking Games team on design, development, art, and promotion to bring their vision to life. Breaking Games is proud to produce some today’s most innovative family, strategy and party games.

Submit the press release

Submit the press release

The security industry’s coveted Global Excellence Awards winners and finalists from all over the world were honored by Info Security Products Guide in San Francisco on Feb. 13, 2017

COLUMBIA, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) — EventTracker, a security information and event management (SIEM) technology innovator, today announced that Info Security Products Guide, the industry’s leading information security research and advisory guide, has named EventTracker v8.2 a gold winner at the 2017 Global Excellence Awards® in SIEM and a silver winner in Managed Security Service. The security industry celebrated its 13th Annual 2017 Global Excellence Awards in San Francisco by honoring excellence in every facet of the industry including products, people behind the successes, and best companies.

/EIN News/ — More than 40 judges from a broad spectrum of industry voices from around the world participated, and their average scores determined the 2017 Global Excellence Awards finalists and winners. Winners were announced during the awards dinner and presentation on Feb. 13, 2017 in San Francisco attended by the finalists, judges, and industry peers.

EventTracker technology is comprehensive and complete with modules for every facet of security monitoring. In addition to basic log management and advanced SIEM features, EventTracker also includes support for behavior anomaly detection, threat intelligence integration, correlation, alerting, and flexible reporting. Modules for intrusion detection systems (IDS), vulnerability scanning, network and flow monitoring and now a HoneyNet deception framework are also available.

EventTracker is unique in the industry as a vendor that offers both best-in-class SIEM technology for self-service and a 24/7 intelligence-driven security operations center (SOC) to provide a fully managed service. This is a critical differentiator because the skill shortage of experienced analysts is the leading cause of SIEM products becoming unused shelfware.

“Info Security Products Guide’s recognition of EventTracker v8.2 further validates our product as excellence-in-class. We enable our customers to not only invest in technology but the outcome they desire—protecting their network and sensitive data from today’s evolving threat landscape,” said A.N. Ananth, CEO of EventTracker. “This industry honor is the greatest endorsement to the fact that EventTracker v8.2 is ahead of the curve when it comes to the best-of-the-best products that can provide the highest levels of security in the SIEM and managed security service markets.”

Tweet this: .@LogTalk (EventTracker) wins in #SIEM, #managedsecurity categories at Global Excellence Awards http://bit.ly/2l9jgLM

Resources
EventTracker v8.2
EventTracker YouTube 
EventTracker Case Studies 

About Info Security Products Guide
Info Security Products Guide plays a vital role in keeping end-users informed of the choices they can make when it comes to protecting their digital resources. It is written expressly for those who are adamant on staying informed of security threats and the preventive measure they can take. You will discover a wealth of information in this guide including tomorrow’s technology today, best deployment scenarios, people and technologies shaping info security and market research reports that facilitate in making the most pertinent security decisions. The Info Security Products Guide Global Excellence Awards recognize and honor excellence in all areas of information security. To learn more, visit www.infosecurityproductsguide.com and stay secured.

About EventTracker
EventTracker’s advanced security solutions protect enterprises and small businesses from data breaches and insider fraud, and streamline regulatory compliance. The company’s EventTracker platform comprises SIEM, vulnerability scanning, intrusion detection, behavior analytics, a honeynet deception network and other defense in-depth capabilities within a single management platform. The company complements its state-of-the-art technology with 24/7 managed services from its global security operations center (SOC) to ensure its customers achieve desired outcomes—safer networks, better endpoint security, earlier detection of intrusion, and relevant and specific threat intelligence. The company serves the retail, hospitality, healthcare, legal, banking and financial services, utilities and government sectors.

EventTracker is a division of Netsurion, a leader in remotely-managed IT security services that protect multi-location businesses’ information, payment systems and on-premise public and private Wi-Fi networks. www.eventtracker.com. Twitter: @logtalk.

CONTACT:
                    Deb Montner, Montner Tech PR
                    (203) 226-9290
                    [email protected]

Contacts:
                    
                    Richard Eisenstadt          
                    Chief Financial Officer     
                    Neos Therapeutics           
                    (972) 408-1389              
                    [email protected]      
                    
                    Sarah McCabe
                    Vice President
                    Stern Investor Relations, Inc.
                    (212) 362-1200
                    [email protected] 

Investor Contact:
                    
                    Pacira Pharmaceuticals, Inc.
                    Susan Mesco, (973) 451-4030
                    [email protected] 

Submit the press release

Submit the press release

The Automotive Remote Diagnostics Market research report is a professional and in-depth study on the current state also focuses on the major drivers and restraints for the key players. Global Automotive Remote Diagnostics Market is Projected to grow at 14.07% CAGR during the period 2016-2020. Automotive Remote Diagnostics Industry research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.

Automotive remote diagnostics or remote vehicle diagnostics as a solution that enables automation of vehicle health and diagnosis using a wireless network. Vehicle health check refers to monitoring vehicle performance by continuously checking and assessing real time data of certain parameters.

This process helps to identify any deviation against expected vehicle performance. Diagnosis refers to the investigation based on real-time vehicle data associated with vehicle performance parameter deviation and the determination of root causes of the deviation. This technology offers several business benefits to both customers and OEMs by enabling an effective vehicle health planner.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Global Automotive Remote Diagnostics Market Research Report @

http://www.360marketupdates.com/10289893

The Automotive Remote Diagnostics Market research report covers the present scenario and the growth prospects of the global Automotive Remote Diagnostics industry for 2016-2020.

Key Vendors of Automotive Remote Diagnostics Market:

• Robert Bosch GmbH
• Continental AG
• OnStar
• Vector
• Vidiwave

And many more…

Automotive Remote Diagnostics market report provides key statistics on the market status of the Automotive Remote Diagnostics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Automotive Remote Diagnostics industry.

Get Sample PDF @

http://www.360marketupdates.com/enquiry/request-sample/10289893

Market Drivers:

• Expanding used passenger and commercial vehicles market
• For a full, detailed list, view our report

Market Challenge:

• Satisfaction gained from low cost aftermarket components
• For a full, detailed list, view our report

Market Trend:

• Increasing mobile phone integration with the telematics system and vehicle diagnostics based insurance programs
• For a full, detailed list, view our report

The Automotive Remote Diagnostics market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the Automotive Remote Diagnostics industry. Automotive Remote Diagnostics market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and Automotive Remote Diagnostics market demand and supply scenarios.

For Any Query, Contact Our Expert @

http://www.360marketupdates.com/enquiry/pre-order-enquiry/10289893

Geographical Regions of Automotive Remote Diagnostics market:

• Americas
• APAC
• EMEA

Key questions answered in Automotive Remote Diagnostics market report:

• What are the key trends in Automotive Remote Diagnostics market?
• What are the Growth Challenges of this market?
• What will the market size & growth be in 2020?
• What are the key factors driving this market?
• Who are the key vendors in this market space?
• How key drivers and challenges impact this market?
• What are the strengths and weaknesses of the key vendors?
• What are the Automotive Remote Diagnostics market opportunities, market risk and market overview?
• How revenue of this Automotive Remote Diagnostics market in previous & next coming years?

The report then estimates 2016-2020 market development trends of Automotive Remote Diagnostics market. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Automotive Remote Diagnostics market before evaluating its feasibility.

Price of Report: $2500 (Single User License)

Purchase Report @

http://www.360marketupdates.com/purchase/10289893

Automotive Remote Diagnostics Market Report Covered:

• Possibility of the Automotive Remote Diagnostics market
• Market research methodology
• Market landscape
• Market segmentation by type
• Geographical segmentation
• Automotive Remote Diagnostics Market drivers
• Market challenges
• Market trends
• Vendor landscape
• Key vendor analysis
• List of Exhibits in Automotive Remote Diagnostics market report:

And continued…

 

About 360 Market Updates:

360 Market Sales Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

 

Contact–

Mr. Ameya Pingaley

360 Market Updates

+1 408 520 9750

Email – [email protected]